Liquidia Corporation (NASDAQ: LQDA) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
88.38
+4.53+5.40%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | 0.14 | Insider Own | 17.55% | Shs Outstand | 88.93M | Perf Week | 1.80% |
| Market Cap | 7.86B | Forward P/E | 15.07 | EPS next Y | 5.86 | Insider Trans | -20.53% | Shs Float | 62.34M | Perf Month | 11.58% |
| Enterprise Value | 7.82B | PEG | 25.13 | EPS next Q | - | Inst Own | - | Short Float | 19.78% | Perf Quarter | 129.68% |
| Income | 22.00M | P/S | 27.29 | EPS this Y | 2268.56% | Inst Trans | - | Short Ratio | 6.53 | Perf Half Y | 99.91% |
| Sales | 288.00M | P/B | 72.11 | EPS next Y | 76.85% | ROA | 5.55% | Short Interest | 12.33M | Perf YTD | 156.25% |
| Book/sh | 1.23 | P/C | 35.24 | EPS next 5Y | 25.12% | ROE | 46.82% | 52W High | 91.10 -2.99% | Perf Year | 399.89% |
| Cash/sh | 2.51 | P/FCF | 181.78 | EPS past 3/5Y | - | ROIC | 12.79% | 52W Low | 17.82 395.96% | Perf 3Y | 1038.92% |
| Dividend Est. | - | EV/EBITDA | 144.82 | Sales past 3/5Y | 114.54% 175.25% | Gross Margin | 91.78% | Volatility | 5.67% 6.41% | Perf 5Y | 3613.45% |
| Dividend TTM | - | EV/Sales | 27.15 | EPS Y/Y TTM | 108.43% | Oper. Margin | 15.81% | ATR (14) | 5.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.03 | Sales Y/Y TTM | 1957.14% | Profit Margin | 7.74% | RSI (14) | 62.37 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.22 | EPS Q/Q | 215.56% | SMA20 | 7.72% | Beta | 0.56 | Target Price | 88.78 |
| Payout | 0.00% | Debt/Eq | 4.38 | Sales Q/Q | 4333.33% | SMA50 | 19.07% | Rel Volume | 0.56 | Prev Close | 83.85 |
| Employees | 216 | LT Debt/Eq | 3.09 | Earnings | Aug 12 | SMA200 | 93.95% | Avg Volume | 1.98M | Price | 88.38 |
| IPO Date | Jul 26, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 26.78% 11.24% | Net Debt/EBITDA | -0.71 | Volume | 1,110,979 | Change | 5.40% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | H.C. Wainwright | Buy | $130 → $36 |
| Jul-24-26 | Reiterated | Piper Sandler | $129 | |
| Jul-24-26 | Reiterated | RBC Capital | $130 | |
| Jul-24-26 | Reiterated | Stephens | $130 | |
| Jul-23-26 | Reiterated | H.C. Wainwright | Buy | $75 → $130 |
| Jun-22-26 | Reiterated | BTIG | Buy | $59 → $109 |
| Jun-05-26 | Reiterated | H.C. Wainwright | Buy | $67 → $75 |
| Jun-05-26 | Reiterated | Oppenheimer | $13 → $75 | |
| Jun-04-26 | Reiterated | Raymond James | Strong Buy | $47 → $68 |
| May-12-26 | Reiterated | H.C. Wainwright | Buy | $55 → $67 |
Latest News
Jul-31-26
Jul-29-26
Jul-29-2608:30AM
Jul-28-26
Jul-28-2608:42AM
Jul-24-26
Jul-23-26
Jul-22-26
Jul-20-26
Jul-20-2611:00AM
Jul-13-26
Jul-13-2608:29PM
01:40PM
Jul-10-26
Jul-09-26
Jul-07-26
11:00AM
Jul-03-26
Company
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 288 | 158 | 14 | 17 | 16 | 13 | 1 | 8 | 3 | |
| Cost of Goods Sold Incl. D&A | 23 | 13 | 6 | 3 | 3 | 3 | 0 | 1 | 0 | |
| Gross Profit | 265 | 145 | 8 | 15 | 13 | 10 | 1 | 7 | 3 | |
| Selling, General and Administrative Excl. Other | 174 | 157 | 82 | 45 | 32 | 23 | 27 | 14 | 9 | |
| Research and Development | 44 | 39 | 48 | 43 | 19 | 21 | 32 | 40 | 29 | |
| Other Operating Expense | 0 | 0 | -1 | 0 | 1 | 0 | 1 | 0 | -1 | |
| Operating Income | 46 | -51 | -121 | -73 | -39 | -34 | -59 | -47 | -35 | |
| Interest Expense | 26 | 24 | 12 | 6 | 2 | 1 | 1 | 1 | 19 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 7 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | |
| Net Income Before Taxes | 26 | -69 | -130 | -79 | -41 | -35 | -60 | -48 | -53 | |
| Income Taxes | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | 22 | -69 | -130 | -79 | -41 | -35 | -60 | -48 | -53 | |
| Net Income From Continuing Operations | 22 | -69 | -130 | -79 | -41 | -35 | -60 | -48 | -53 | |
| Net Income | 22 | -69 | -130 | -79 | -41 | -35 | -60 | -48 | -53 | |
| EPS (Recurring) | 0.24 | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | |
| EPS (Basic, Before Extraordinaries) | 0.24 | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | |
| EPS (Diluted) | 0.14 | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | |
| EBITDA | 54 | -43 | -116 | -70 | -35 | -28 | -56 | -43 | -33 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 631.29 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 27.01 | 18.77 | 66.36 | 46.00 | 24.29 | 18.73 | 100.30 | 9.62 | 50.54 | |
| Gross Margin | 92.01 | 91.77 | 57.14 | 88.24 | 81.25 | 76.92 | 100.00 | 87.50 | 100.00 | |
| Operating Margin | 15.97 | -32.28 | -864.29 | -429.41 | -243.75 | -261.54 | -5,900.00 | -587.50 | -1,166.67 | |
| Net Margin | 7.64 | -43.67 | -928.57 | -464.71 | -256.25 | -269.23 | -6,000.00 | -600.00 | -1,766.67 | |
| Shares Outstanding | 88 | 86 | 79 | 65 | 61 | 50 | 34 | 18 | 7 | |
| Market Capitalization | 7,777 | 2,966 | 929 | 782 | 389 | 244 | 100 | 77 | 152 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Boyle Dana | Chief Accounting Officer | Jul 27 '26 | Sale | 87.53 | 1,600 | 140,048 | 167,919 | Jul 29 |
| Adair Jason | Chief Business Officer | Jul 27 '26 | Sale | 87.53 | 688 | 60,221 | 216,438 | Jul 29 |
| Bloch Stephen M | Director | Jul 23 '26 | Sale | 89.48 | 100,000 | 8,948,443 | 501,477 | Jul 24 |
| Bloch Stephen M | Director | Jul 22 '26 | Sale | 88.38 | 100,000 | 8,837,964 | 601,477 | Jul 24 |
| Bloch Stephen M | Director | Jul 21 '26 | Sale | 79.99 | 75,000 | 5,999,182 | 701,477 | Jul 22 |
| Bloch Stephen M | Director | Jul 20 '26 | Sale | 79.55 | 3,596 | 286,068 | 776,477 | Jul 22 |
| Boyle Dana | Chief Accounting Officer | Jul 13 '26 | Sale | 71.51 | 9,002 | 643,740 | 169,519 | Jul 14 |
| Krepp Sarah | Chief Human Resource Officer | Jul 13 '26 | Sale | 71.51 | 7,864 | 562,361 | 117,178 | Jul 14 |
| Khindri Sanjeev | Chief Development Officer | Jul 13 '26 | Sale | 71.51 | 1,185 | 84,741 | 65,947 | Jul 14 |
| Kaseta Michael | CFO and COO | Jul 13 '26 | Sale | 71.51 | 20,430 | 1,460,965 | 345,805 | Jul 14 |
| JEFFS ROGER | Chief Executive Officer | Jul 13 '26 | Sale | 71.51 | 35,249 | 2,520,683 | 1,130,426 | Jul 14 |
| Adair Jason | Chief Business Officer | Jul 13 '26 | Sale | 71.51 | 7,863 | 562,289 | 217,126 | Jul 14 |
| Schundler Russell | General Counsel | Jul 13 '26 | Sale | 71.51 | 14,738 | 1,053,926 | 605,962 | Jul 14 |
| Saggar Rajeev | Chief Medical Officer | Jul 13 '26 | Sale | 71.51 | 9,926 | 709,816 | 171,799 | Jul 14 |
| Moomaw Scott | Chief Commercial Officer | Jul 13 '26 | Sale | 71.51 | 9,539 | 682,141 | 182,485 | Jul 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.